RxDoctor Payments Data

Timekia Hill

Nurse Practitioner · Spartanburg, SCNPI 1326542887

Payments from drug & device makers

$3,443in general payments, 2019–2025

Across 190 payments — averaging $18.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$769
  • AbbVie$703
  • Alkermes, Inc.$588
  • Johnson & Johnson$566
  • E.r. Squibb & Sons, L.L.C.$370
  • Otsuka America Pharmaceutical, Inc.$183
  • plus $263 from 7 others

What the payments were for

  • Food & beverage$3,30996%
  • Education$1344%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,443 in reported general payments places this provider in the 90th percentile of 1,346 nurse practitioner providers in South Carolina.

See all nurse practitioner providers in South Carolina

Medicare billing

Part B allowed, 2024
$7,393
Medicare patients
32
Services billed
80

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate73$225,972
Invega TrinzaPaliperidone Palmitate23$184,841
Abilify MaintenaAripiprazole53$150,444
IngrezzaValbenazine Tosylate12$114,101
VraylarCariprazine Hcl62$94,516
Paliperidone ErPaliperidone54$8,755
TrintellixVortioxetine Hydrobromide13$6,256
Aripiprazole106$4,436
Quetiapine Fumarate174$2,429
Olanzapine118$2,063
Duloxetine Hcl110$1,245
Buspirone Hcl130$1,235
Mirtazapine110$1,188
Venlafaxine Hcl ErVenlafaxine Hcl45$1,086
Ziprasidone Hcl38$1,034

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$566$410,81496 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$183$150,44453 claims
Neurocrine Biosciences, Inc.Ingrezza$76$114,10112 claims
AbbVieVraylar$703$94,51662 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,346 nurse practitioner providers in South Carolina.

Other nurse practitioner in Spartanburg

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →